Effect of oral semaglutide on energy intake, appetite, control of eating and gastric emptying in adults living with obesity: A randomized controlled trial
Primary result · Relative change from baseline in ad libitum energy intakeResult — go to the resultDifference −39.2 % points 95% CI −59.0% to −19.4%Authors' conclusion
In participants with obesity, once-daily oral semaglutide 50 mg reduced energy intake, body weight and appetite, and improved control of eating. There was no evidence of delayed gastric emptying at week 20, as measured through paracetamol absorption.
Study context
- Population
- Adults with obesity
- Participants
- 61 adults
- Comparison
- Once-daily oral semaglutide 50 mg vs placebo for 20 weeks
- Primary endpoint
- Relative change from baseline in ad libitum energy intake
- Follow-up
- Week 20
Methodological detailsdouble-blind, clinical pharmacology study
- Double-blind
- Clinical pharmacology study
Primary result
As reported in the abstract
Difference
−39.2 % points
95% CI −59.0% to −19.4%
Semaglutidevs Placebo
difference −39.2 % points (95% CI −59.0% to −19.4%)
Further findings
Body weight reduction
Appetite and control of eating
- Semaglutide reduced hunger, increased fullness and satiety, and was associated with fewer food cravings and better control of eating vs placebo
Gastric emptying (paracetamol absorption) · week 20
- No statistically significant difference in gastric emptying
Original publication
Effect of oral semaglutide on energy intake, appetite, control of eating and gastric emptying in adults living with obesity: A randomized controlled trial. Diabetes Obes Metab. Published 31 July 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →